Histology Shift in Esophageal Cancer Between Biopsies and Resections After Neoadjuvant Therapy: A Pilot Study
International Journal of Surgical Pathology · 2024
DOI: 10.1177/10668969231208029 ↗Kurz gefasst
Fachartikel in der Zeitschrift International Journal of Surgical Pathology, 2024. Verfasst von Tieying Hou und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pathology and Laboratory Medicine, Indiana University School of Medicine, Indianapolis, IN, USA. Hauptthemen laut MEDLINE: Esophageal Neoplasms, Neoadjuvant Therapy, Adenocarcinoma, Esophagectomy. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 19 Literaturangaben.
Abstract (Originalsprache)
Preoperative neoadjuvant therapy followed by resection is the mainstay treatment for locally advanced esophageal adenocarcinoma. We recently observed the histology shift from predominant esophageal adenocarcinoma in the biopsy to neuroendocrine neoplasm with or without adenocarcinoma in the post-treatment resection. The underlying mechanism of this finding is uncertain, and there is limited information in the literature. A total of 11 patients were identified: 10 patients received presurgical chemoradiation and 1 with chemotherapy. All biopsies were diagnosed with adenocarcinoma. When neuroendocrine immunomarkers were retrospectively performed on 5 biopsies, 2 showed focal positivity, although the classic neuroendocrine morphology was not readily appreciated. All resections contained neuroendocrine neoplasm, including 8 of well-differentiated type and 3 of neuroendocrine carcinomas. Two post-treatment esophagectomies consisted of neuroendocrine neoplasm only without residual adenocarcinoma. Upon follow-up, 8 patients died of the disease (median survival = 26 months), and 3 patients were alive after a median follow-up of 14 months. The overall median survival time was better than the reported esophageal neuroendocrine carcinoma (15 months). The 5-year observed survival rate was 11.3%, which was lower than the Surveillance, Epidemiology, and End Results 5-year survival rate of adenocarcinoma (21.8%). We reported a small series of esophageal adenocarcinoma that showed histology shift between biopsy and esophagectomy after neoadjuvant therapy. Our limited data suggest that prognosis of this group is different than the conventional adenocarcinoma. Awareness of this morphological change reminds pathologists to examine the biopsy specimens thoroughly, because recognition of neuroendocrine neoplasm, especially high-grade neuroendocrine component, might potentially affect pre- and post-surgical regimens.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Pathology and Laboratory Medicine, Indiana University School of Medicine, Indianapolis, IN, USA.
- Department of Pathology and Laboratory Medicine, University of Pennsylvania, Philadelphia, PA, USA.
- Department of Pathology, Yale University School of Medicine, New Haven, CT, USA.
- Department of Pathology and Laboratory Medicine, University of Rochester Medical Center, Rochester, NY, USA.
ORCID-Profile: Tieying Hou, Zhaohai Yang, Xuchen Zhang, Xiaoyan Liao
Zitieren
APA
Hou, T., Yang, Z., Zhang, Q., Zhang, X., Liao, X., & Lin, J. (2024). Histology Shift in Esophageal Cancer Between Biopsies and Resections After Neoadjuvant Therapy: A Pilot Study. International Journal of Surgical Pathology. https://doi.org/10.1177/10668969231208029
Vancouver
Hou T, Yang Z, Zhang Q, Zhang X, Liao X, Lin J. Histology Shift in Esophageal Cancer Between Biopsies and Resections After Neoadjuvant Therapy: A Pilot Study. International Journal of Surgical Pathology. 2024. doi:10.1177/10668969231208029
BibTeX
@article{Hou2024,
author = {Hou, Tieying and Yang, Zhaohai and Zhang, Qingzhao and Zhang, Xuchen and Liao, Xiaoyan and Lin, Jingmei},
title = {Histology Shift in Esophageal Cancer Between Biopsies and Resections After Neoadjuvant Therapy: A Pilot Study},
journal = {International Journal of Surgical Pathology},
year = {2024},
doi = {10.1177/10668969231208029}
}
EUVIMED